Navigation Links
Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
Date:11/23/2009

e time point on reduction of spontaneous pain, hyperalgesia (increased sensitivity to pain) and allodynia (pain due to a stimulus which does not normally provoke pain). After the 120 minute time point, the 90 mg dose was statistically significant for hyperalgesia and allodynia. NGX426 was well tolerated, all subjects completed the three treatment periods, and the most common adverse events attributed to NGX426 were mild somnolence and dizziness.

Dr. Wallace commented, "Human experimental models of pain, such as this used in this study, are emerging as tools to predict efficacy of novel analgesics early in the clinical trial process. These results for NGX426 are exciting because they suggest that this drug could be effective in real-world, clinical pain states. Having worked in both patient care and in the research of state of the art therapies for the management of chronic pain, I'm always excited to see a new potential product deliver encouraging data. These proof-of-concept results support further clinical development for NGX426 as well as its companion drug, tezampanel, as potential non-opioid treatments for pain."

Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, commented, "We are encouraged by these results suggesting that NGX426 could be effective in the treatment of acute pain such as migraine and chronic pain, such as neuropathy. NGX426 has been administered to 182 male and female healthy subjects in single and multiple doses and all doses of NGX426 were well-tolerated with no serious or medically important adverse events reported. We believe the pain indication could benefit from such a safety profile and potential efficacy profile. We plan to continue to explore our options with NGX426 in the treatment of pain, and we are actively looking for partners or collaborators regarding the development of this product candidate."

About Raptor Pharmaceutical Corp.


Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  Diplomat, the nation,s largest independent specialty pharmacy, has ... the Board of Directors on September 15, 2014. Mr. ... as chair of the Audit Committee. ... compliance and operating experience in the health care field.  ... financial officer, chief operating officer and secretary of Patient ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... diagnostics, issued the following statement today in support of ... Bacteria. "As the global leader in rapid ... establishing a national strategy to address the serious threat ... work with the Administration on initiatives to promote the ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today that ... notes. The Company intends to use the ... of the outstanding borrowings under its credit facility and for ... Smith Incorporated, BNP Paribas Securities Corp. and RBS Securities Inc. ...
... 7, 2011 Vermillion, Inc. (NASDAQ: ... to present at the Stephens Fall Investment Conference. The conference ... New York City on November 15-16, 2011. Vermillion,s ... Wednesday, November 16, 2011 at 10:30 a.m. Eastern time, with ...
Cached Medicine Technology:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011 2
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... 21, 2014 The Illinois Joining ... host a statewide symposium ( tinyurl.com/ILBHC14 ) focused ... their Families. Sponsored by the VNA Foundation, Thresholds, ... Grant, and Health & Disability Advocates, the symposium ... Hilton Hotel in Springfield, IL. The symposium ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... implements and supports electronic medical records (EMR) and ... from federal healthcare legislation during the past five ... so during the five years to 2019. The ... Health Act established Medicare and Medicaid incentives to ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes ... its decision to implement a new shopping cart software ... across the world. Furthermore, the company has unveiled a ... , The new items come in fashionable designs; all ... to 56 percent off. "We are happy to release ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2
... million, Five-year Grant, from New York State Department of,Health, ... Lead,Poisoned, NEW YORK, Feb. 11 The Lead ... Montefiore,(CHAM) has been named one of three State Regional ... healthcare delivery for children and,pregnant women with elevated blood ...
... Part of MedCath,s Growth Plans, CHARLOTTE, N.C., Feb. ... physician partners today announced plans to double,the number of ... a 120-bed acute care and heart hospital., The ... into 60 inpatient beds, which will be used to ...
... from the UC Davis M.I.N.D. Institute shows that an ... be linked with the repetitive behavior also called ... studies are needed to confirm the outcome, this result ... prenatal period could be a causal factor for the ...
... SOUTH SAN FRANCISCO, Calif., Feb. 11 ... SpA have announced an agreement granting,an exclusive ... distribution of,Anesiva,s Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... France,Germany, Netherlands, Belgium and Luxembourg. Under the ...
... Unlike other epilepsy meds, Trileptal was no better than ... -- The epilepsy drug oxcarbazepine (Trileptal) does not seem ... finds. , Migraines affect more than 28 million Americans, ... effective in preventing these severe headaches. For this reason, ...
... American Academy of ... Dermatology, ... that validates the benefits of alpha-hydroxy acid (AHA),at- home peels in ... as lasers and microdermabrasion. The,data were highlighted in the Poster Session ...
Cached Medicine News:Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 3Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 2Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 3Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 2Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 3Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2
Comes complete with its own case. A unique integrated design with no need for two separate bars., ,Optical surfaces are recessed for optimum protection. Extensive prism power 1,2,3,4,6,8,10,15,20...
Well established test for children but suitable for disabled people, those with learning difficulties or patients who do not share a common language with the examiner....
... Carotid Stent System is designed to provide easy ... carotid atherosclerosis and are at high risk for ... RX ACCULINK Carotid Stent System is 6F sheath/8F ... The RX ACCULINK utilizes rapid exchange (RX) technology ...
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
Medicine Products: